Search results
FDA panel rejects MDMA-assisted therapies for PTSD despite high hopes from veterans
Fox News· 2 days agoA U.S. Food and Drug Administration (FDA) panel rejected MDMA-based treatments for post-traumatic...
The FDA Should Reject MDMA Therapy—but Not for the Reasons You Think
Slate· 1 day agoThe FDA will officially vote Aug. 11 on whether to approve the treatment. The agency isn’t required...
Why FDA Panel Rejected MDMA Therapy—And What’s Next For Psychedelic Medicine
Forbes· 1 day agoAs far back as the 1970s, MDMA was used by mental health professionals in conjunction with talking ...
With MDMA debate spreading beyond biotech, Lykos CEO tries to dispel efficacy, safety concerns
FierceBiotech· 1 day agoA week after an FDA committee declined to support an midomafetamine (MDMA) treatment for...
MDMA’s Future As A Treatment For PTSD Is In Question
Inverse· 4 days agoWhile the FDA will still vote separately on MDMA, it generally follows the recommendation of its advisors, so its unlikely the novel treatment will gain approval. The drug ...
Trouble for ecstasy? What MDMA’s FDA setback could mean for psychedelics
NPR· 2 days agoGeneral Hospital, who presented on behalf of Lykos about the need for more PTSD treatment. Gorman acknowledges the Lykos' therapy protocol is more “open-ended ...
Opinion | Was the FDA Panel Right to Recommend Against MDMA Approval?
MedPage Today· 4 days agoPatients with PTSD should be given the same promise of scientific rigor as those with any other...
Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know.
Motley Fool via Yahoo Finance· 4 days agoIf you're not familiar, MDMA is known by the street names ecstasy or molly, and while still...that...
Unease as US drug agency weighs its use of independent scientists
Nature· 23 hours agoAfter several controversial drug approvals, the US Food and Drug Administration is mulling changes...
Alzheimer’s drug with modest benefits wins backing of FDA advisers
Nature· 5 days agoDonanemab slows progression of symptoms, but questions linger about the durability of its effect.